** U.S.-listed shares of Biofrontera Inc fall 11% to 74 cents
** On Wednesday, company reported Q3 rev. of $9 mln, missing two analysts' average est. of $10 mln, due to disruption from hurricanes
** Q3 loss of 98 cents/shr wider than est. loss of 84 cents/shr, according to data compiled by LSEG
** BFRI likely to report strong Q4 revenue, as demand for Ameluz, company's treatment for a type of skin condition, increases in less-sunny weather - Brokerage Roth MKM
** Company to also benefit from Ameluz price hike of October and hurricane-interrupted sales moving into the quarter - Roth MKM
** Including session gains, BFRI down 73.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Comments